Media.Player

Method of Preventing Bone Loss and Periodontal Disease

技術優勢

Cost effective treatmentLow potential for side effectsPromotes the understanding of a crucial inflammatory system

技術應用

Subjects having osteoporosis or periodontal disease Subjects having a bone fracture or broken bone Subjects who are exhibiting symptoms of bone loss Subjects who are suffering bone loss Subjects who may benefit from promotion of bone growth or regeneration

詳細技術說明

Bone homeostasis is maintained by a balance between bone resorption by osteoclasts and bone formation by osteoblasts. The anti-inflammatory system triad composed of RANK, RANK-L, and OPG orchestrates bone homeostasis by selectively activating osteoclasts and osteoblasts in a regulated fashion. In chronic osteolytic inflammatory diseases, such as periodontitis, the failure of endogenous resolution pathways seem to lead to bone loss and tissue destruction. Precise regulation of the RANK, RANK-L, and OPG triad promises a solution to this disease and many others. Researchers at the University of California, Davis have developed a method to regulate the RANK, RANK-L, and OPG signaling pathway. This method regulates the signaling system to limit inflammation, cancer, arthritic disease, and bone loss while promoting bone growth, remodeling, and regeneration. This method is based on the elevation and regulation of epoxy fatty acid (EpFA) levels, which is accomplished by the inhibition of the enzyme, soluble epoxide hydrolase (sEH). This method has proven effective to reduce bone loss in mice infected with periodontitis. Bioactive compounds are available that can be used topically for periodontal disease and have good pharmacokinetics and high oral availability for oral administration.

*Abstract

A method of controlling mammalian epoxy fatty acids levels in order to regulate the RANK, RANK-L, and OPG anti-inflammatory triad, thereby limiting inflammation, cancer, arthritic disease, and bone loss while promoting bone growth, remodeling, and regeneration.

*IP Issue Date

Dec 14, 2017

*Principal Investigation

Name: Ahmed Bettaieb

Department:

Name: Fawaz Haj

Department:

Name: Bruce Hammock

Department:

Name: Bora Inceoglu

Department:

Name: Carlos Trindade da Silva

Department:

Name: Ahmet Inceoglu

Department:

其他

Additional Technologies by these Inventors

• Brown Adipose Tissue Cell Lines Derived from Protein-Tyrosine Phosphatase 1B Knockout Mice Reconstituted with Sumoylation Mutant PTP1B K4R
• Improved Dioxin Detection and Measurement
• Recombinant Neurotoxin: A More Effective Insecticide
• Antibodies: Urea Herbicide Pabs
• Antibodies: Triazine Herbicide Pabs
• Antibodies: Bacillus Delta Endotoxin PAbs
• Antibodies: Bromacil Herbicide PAbs
• Novel and Specific Inhibitors of p21
• Beneficial Effects of Novel Inhibitors of Soluble Epoxide Hydrolase as Adjuvant Treatment for Cardiac Cell-Based Therapy
• Novel Neuropathy Treatment Using Soluble Epoxide Inhibitors
• Detection System for Small Molecules
• Methods and Compositions of Treating Diabetic Nephropathy and Insulin Resistance
• A New Pharmaceutical Therapy Target for Depression and Other Central Nervous System Diseases
• Multi-Target Inhibitors for Pain Treatment
• Antibodies for Pseudomonas (P.) aeruginosa
• Chemical Synthesis of Lipid Mediator 22-HDoHE and Structural Analogs
• Soluble Epoxide Hydrolase-Conditioned Stem Cells for Cardiac Cell-Based Therapy
• PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity
• Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders
• Bioavailable Dual sEH/PDE4 Inhibitor for Inflammatory Pain

Tech ID/UC Case

27144/2016-206-0

Related Cases

2016-206-0

國家/地區

美國